title: Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome.
abstract: OBJECTIVE
  To test whether the follicular fluid (FF) concentration of anti-Mullerian hormone (AMH) is associated with oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome (PCOS) undergoing IVF.
  
  
  METHODS
  Prospective.
  
  
  METHODS
  Academic assisted reproductive technology program.
  
  
  METHODS
  Twenty-two samples of FF from 11 patients with PCOS who underwent IVF/ET were analyzed for AMH levels (group A). Twelve women with normal ovulatory cycles served as a control group (group B). The oocytes and preembryos were closely followed until ET.
  
  
  METHODS
  FF was obtained at oocyte retrieval for IVF/intracytoplasmic sperm injection. AMH levels were studied using immunoenzymometric assay.
  
  
  METHODS
  None.
  
  
  METHODS
  FF, AMH levels, oocyte maturation, fertility rate, and embryonic cleavage rate.
  
  
  RESULTS
  The mean FF AMH level was 57.3 +/- 79.5 pmol/mL in group A, compared with 70 +/- 120.14 pmol/mL in group B. In group A, the mean AMH level of good-quality embryos was 37.4 +/- 23.4 pmol/mL, compared with 61.9 +/- 102 pmol/mL in a the poor-quality subgroup. No significant correlation was observed between FF AMH levels and oocyte maturation, fertilization, or cleavage rate.
  
  
  CONCLUSIONS
  This study suggests that there is an association between FF AMH levels and the quality of embryos in patients with PCOS. However, owing to large variance and the number of participants, no statistical significance was reached. The degree of maturation of retrieved oocytes, as well as the success of fertilization, was not found to correlate with FF AMH.
authors.affiliation: IVF Unit, Department of Obstetrics and Gynecology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: Roy
authors.initials: R
authors.lastname: Mashiach
authors.forename: Ami
authors.initials: A
authors.lastname: Amit
authors.forename: Joseph
authors.initials: J
authors.lastname: Hasson
authors.forename: Sagi
authors.initials: S
authors.lastname: Amzalzg
authors.forename: Beni
authors.initials: B
authors.lastname: Almog
authors.forename: Dalit
authors.initials: D
authors.lastname: Ben-Yosef
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Lessing
authors.forename: Rona
authors.initials: R
authors.lastname: Limor
authors.forename: Foad
authors.initials: F
authors.lastname: Azem
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000032:analysis* / Q000378:metabolism; D047108:Embryonic Development / Q000502:physiology*; D005260:Female; D005306:Fertilization / Q000502:physiology; D005307:Fertilization in Vitro / Q000379:methods; D015571:Follicular Fluid / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D007247:Infertility, Female / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D009865:Oocytes / Q000502:physiology*; D009866:Oogenesis / Q000502:physiology; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D011237:Predictive Value of Tests; D011247:Pregnancy; D018873:Pregnancy Rate; D011379:Prognosis
chemical_list: D054304:Anti-Mullerian Hormone